Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Drop in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 6,999 shares, a decline of 69.2% from the April 15th total of 22,704 shares. Currently, 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 33,057 shares, the days-to-cover ratio is presently 0.2 days.

Bolt Biotherapeutics Price Performance

BOLT stock traded down $0.05 during trading on Thursday, reaching $4.79. The company’s stock had a trading volume of 7,058 shares, compared to its average volume of 25,300. The company has a quick ratio of 3.59, a current ratio of 3.59 and a debt-to-equity ratio of 0.76. The company’s fifty day moving average is $4.59 and its 200-day moving average is $5.13. The company has a market capitalization of $9.20 million, a P/E ratio of -0.29 and a beta of 1.10. Bolt Biotherapeutics has a 1 year low of $3.91 and a 1 year high of $9.25.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($4.31) EPS for the quarter, missing the consensus estimate of ($2.85) by ($1.46). Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 91.06%. The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. On average, research analysts expect that Bolt Biotherapeutics will post -9.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. T3 Companies LLC purchased a new stake in Bolt Biotherapeutics during the 4th quarter valued at approximately $208,000. Renaissance Technologies LLC lifted its holdings in shares of Bolt Biotherapeutics by 92.2% in the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares in the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in shares of Bolt Biotherapeutics during the fourth quarter worth $112,000. Susquehanna International Group LLP purchased a new position in Bolt Biotherapeutics during the third quarter valued at $89,000. Finally, Shay Capital LLC purchased a new position in Bolt Biotherapeutics during the third quarter valued at $85,000. 86.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Friday, March 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Monday, April 20th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $41.00.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.